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Context
Adrenal crises (AC) cause morbidity and mortality in patients with Addison’s disease
[primary adrenal insufficiency (PAI)]. Patient-initiated oral stress dosing, with parenteral
hydrocortisone, is recommended to avert ACs. While these should be effective, the continued
incidence of ACs remains largely unexplained.
Methods
Audit of all attendances between 2000 and 2017 by adult patients with treated PAI to one
large regional referral centre in New South Wales, Australia. Measurements were those taken
on arrival at hospital.
Results
There were 252 attendances by 56 patients with treated PAI during the study period. Women
comprised 60.7% (n=34) of the patients. The mean age of attendees was 53.7 (19.6) years.
Nearly half (45.2%, n=114) the patients had an infection. There were 61 (24.2%) ACs
diagnosed by the treating clinician. Only 17.9% (n=45) of the hospital presentations followed
any form of stress dosing. IM hydrocortisone was used before 7 (2.8%) attendances only.
Among patients with a clinician diagnosed AC, only 32.8% (n=20) had used stress dosing
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Addison’s disease or primary adrenal insufficiency (PAI) is a rare disorder that affects
approximately 100/million in the population (1,2). In Western countries, PAI is largely due
to autoimmune adrenalitis, a condition that is more common in females and may be
associated with other autoimmune endocrine disorders as part of the autoimmune
polyglandular syndromes (APS 1,2) (1,2). Patients with PAI need lifelong glucocorticoid
replacement therapy and the majority also need mineralocorticoid replacement. Despite
modern approaches to management, patients are at increased risk of morbidity and mortality,
some of which is attributable to adrenal crises (AC) (3-7). These acute episodes of severe AI,
which occur during periods of physiological stress, have an estimated mortality rate of
0.5/100 PY (8).
As ACs are infrequent emergency presentations, there may be uncertainty around the
diagnosis, and misclassifications of symptomatic AI as ACs and vice versa can occur (9).
Adrenal crises can be defined as episodes of acute AI with hypotension that may be
associated with electrolyte abnormalities (hyponatraemia, hyperkalaemia); alterations in
consciousness; and acute abdominal symptoms, that rapidly improve after administration of
intravenous hydrocortisone (9). ACs occur at a rate of approximately 5-8/100 patient years in
treated PAI, may vary in incidence between patient subgroups, and appear to be increasing in
frequency (8-12). Comorbidities, particularly Type 1 diabetes mellitus (T1DM) are thought
to increase the risk of an AC (9,12). In patients with comorbid T1DM, this increase may be
due to difficulties managing the requirements of both conditions during an intercurrent illness
(9,12).
All patients with AI should be educated to increase their glucocorticoid replacement,
“stress dose”, during an episode of physiological stress, most commonly an acute infectionrelated illness. Patients are advised to double or triple their oral glucocorticoid dose in these
situations but, when this cannot be taken or absorbed, for example when there is diarrhoea or
vomiting, or when symptoms are severe or evolving rapidly, patients are advised to
administer an intramuscular (IM) [or subcutaneous (SC)] injection of hydrocortisone and
seek medical attention promptly (2,9, 13, 14, 15). However, the persistent incidence of ACs
in a number of populations suggests that management of AI during episodes of illness is not
always successful, although the reasons for this are not clear. This study aims to identify
factors that may explain the continued occurrence of ACs in patients with treated PAI.
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Methods
The Hunter New England area health service provides health care to a large regional area,
with a population of nearly 1 million people in New South Wales, Australia (16). It
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before presentation. Vomiting was reported by 47.6% (n=120) of the patients but only 33
(27.5%) of these attempted stress dosing and 5 patients with vomiting used IM
hydrocortisone. The number of prior presentations was a significant independent predictor of
use of stress doses [1.05 (1.01,1.09)].
Conclusion
Dose escalation strategies are not used universally or correctly by unwell patients with PAI,
many patients do not use IM or SC hydrocortisone injections. Previous hospital treatment
increases the likelihood of stress dosing and offers the opportunity for reinforcement of
prevention strategies.
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Patient age was analysed as both a continuous variable and according to 10 year age groups.
The number of presentations, admissions, episodes of treatment in which stress dosing had
been reported were coded manually for each patient. For other variables, the following
definitions were used: hyperkalaemia: serum potassium greater than 5.0 mmol/l;
hyponatraemia: serum sodium less than 135 mmol/l; hypoglycaemia: glucose less than 3.5
mmol/l; and hyperglycaemia: glucose greater than 7.0 mmol/l. Hypotension was classified as
a systolic blood pressure (sBP) of 100mg Hg or below. An AC was considered present when
this was recorded in the medical record by the treating clinician (Clin-AC). However, given
the possibility of AC misclassification, ACs with hypotension were further classified as
clinician-diagnosed AC with hypotension (Clin-AC-hypo). Patients with hypotension which
did not have a recognisable non-PAI cause were also identified (hypo-non-Clin-AC). These
two groups of patients were recategorized into a “true AC” group and were compared to the
remaining patients, who were considered to have “symptomatic AI”.
Statistical analysis

The data were analysed using the SPSS software package version (SPSS Statistics Version
25). Differences in continuous variables between groups were assessed using t-tests and,
where the variances were unequal, appropriate significance tests were used. Categorical
variables were evaluated using Chi sq or Fishers exact tests. A logistic regression model was
developed to assess the relationship between demographic and illness-related variables on the
use of stress dosing in the study sample. Wald Chi sq statistics were used to assess the
significance of each variable in the model.
The study was approved by the St Vincent’s Hospital, Sydney HREC, the Hunter New
England Health Service HREC, and the HREC of the University of Notre Dame, Australia.
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comprises a large urban area with smaller semi-urban and some rural areas. There is one
main public referral hospital, another public hospital, a private hospital sector providing some
tertiary services, and a number of smaller local hospitals providing limited services to a local
community (16). Data on all admissions to these hospitals are coded according to the ICD10-AM (17) and stored securely at each health service.
For the purposes of this study, all patients with a diagnosis of an AC (E27.2) or PAI
(E27.1) who had at least one admission to the referral hospital between 2000 and 2017 were
eligible for inclusion. Hospital staff electronically screened the database for all eligible
patient medical record numbers, which were extracted into a dataset. Using these, each
electronic patient record was reviewed remotely using a password protected access code. For
each patient with a confirmed PAI diagnosis, the first admission and all subsequent hospital
attendances during the study period were reviewed. Where a presentation was due to an
acute medical illness, the record was assessed in detail. Each patient was allocated a unique
study number and each attendance was given an episode number linked to the study number.
The following variables were extracted from each eligible presentation: age, sex, principal
diagnosis, comorbid diagnoses, any procedures, whether the patient had used stress dosing
and the type of stress dose, electrolytes, blood pressure on presentation, symptoms of AI, AC
diagnosis, diabetic ketoacidosis (DKA), whether the patient was admitted, length of stay
(LOS) and whether the patient was alive at discharge. Data on each patient was deidentified
and entered into an Excel (Microsoft Excel Version 16.24) database.
For this analysis, only those patients who were receiving treatment for PAI were selected
and episodes of hospital attendance prior to, or for, the initial diagnosis of PAI were
excluded.
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There were 5 (2.0%) in-hospital deaths but in only 1 had an AC been diagnosed but 4 had
been administered IV hydrocortisone. Of the 5 deaths, 3 were patients who had PAI only and
2 had comorbid PAI/T1DM. Of the PAI-only patients, none attempted stress-dosing, none
had an AC recorded and all 3 received IV HC. Causes of death were complex and due to
extensive comorbid disease. The first was due to a fractured neck of femur leading to
cardiorespiratory failure. The second had many diagnoses listed as contributing to the cause
of death including: hepatic encephalopathy, liver failure, aspiration pneumonia, small bowel
obstruction and sepsis. The third was due to multi-system failure (hepatic, renal, respiratory)
as a result of sepsis. Of the 2 deaths from PAI/T1DM patients, none attempted stress-dosing,
one patient had an AC recorded and received IV HC, the other did not receive IV HC. Causes
of death were listed as sepsis from a pressure sore and cerebral anoxia.
Adrenal Crisis Diagnoses and Hypotension

D

In 63 (25.0%) of the presentations a clinician diagnosed AC (Clin-AC) was recorded, and in
21 (33.3%) of these, stress dosing had been used prior to attendance. Almost all (93.7%,
n=59) patients with Clin-AC were given IV hydrocortisone (Table 1). Nearly half (47.6%,
n=30) of these patients had hypotension (Clin-AC-hypo) and the remainder (n=33, 52.4%)
were normotensive. There were 26 (10.3%) patients who were not diagnosed with an AC but
who, on arrival, had hypotension which appeared attributable to PAI (hypo-non-Clin-AC).
These patients were combined with the clin-AC-hypo group as the “true AC” category of
presentations (n=56, 22.2% of all attendances).
Among the patients in the “true AC” category, 31 (55.4%) had hyponatraemia; 13
(23.2%) had hyperkalaemia; 3 (5.4%) had hypoglycaemia; 9 (16.1%) had reduced
consciousness; 15 (26.8%) had used any form of stress dosing; 12 (21.4%) had been stress
dosed orally; and 5 (8.9%) had used IM hydrocortisone. Patients in this group were
significantly younger than the remaining patients (43.5 (18.3) and 56.6 (19.0) years
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The majority (83.7%, n= 211) of the 252 attendances resulted in an admission (Table 1).
Females comprised two thirds (174 (69.0%)) of the of attendees. The mean age of patients
was 53.7 (19.6) years and 29.0% (n=73) were aged 70 or more years. The median LOS was 2
(IQR 1-5) days and 99 (39.3%) admissions were for one day only. Nearly three quarters
(73.4%, n=185) of the patients were treated with IV hydrocortisone (Table 1).
Any form of dose escalation was used by 17.9% (n=45) of the patients prior to
attendance. Oral stress dosing was used before 40 presentations (15.9%) and in 7 (2.8%)
there was a record of prior IM hydrocortisone administration (one of these was administered
by a family doctor). There was no record of SC hydrocortisone administration. Nearly half
(48.4%, n=182) the attendees arrived by ambulance.
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During the period 2000 to 2017, there were 252 attendances by 56 patients with PAI, who
were on glucocorticoid replacement therapy, and who had at least one admission to the study
hospital for an acute illness. This equates to an approximate incidence of one attendance per
patient every three years. Of these 49 (87.5%) patients had non-T1DM PAI and 7 (12.5%)
had both PAI and T1DM. Comorbid thyroid disease was present in 52.0% (n=131) of the
attendees (Table 1). Women comprised 60.7% (n=34) of the patients. Two thirds (66.1%,
n=37) of the patients were found to have never used any kind of stress dosing prior to any
attendance at the study hospital. Of those patients who had stress dosed, 11 (19.6%) had one
recorded attempt at dose escalation, 5 (8.9%) had a record of dose escalation at 2
presentations; and there was 1 patient (1.8%) for each of 3, 6 and 16 separate presentations in
which there was stress dosing before arrival.
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respectively, p<0.001). Patients in the “true AC group” also had a significantly higher
burden of vomiting than the remaining patients (n=40 (71.4%) and n=80 (40.8%)
respectively, p<0.001). Infection (n=32 (57.1%) was more common in the “true AC” group
than in those with symptomatic AI (n=82, 41.8%) (p<0.05) as was a diagnosis of
gastroenteritis (n=14 (25.0%) and n=17 (8.7%) respectively, p<0.01).
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The 7 patients with T1DM and PAI contributed 37 presentations to the study hospital.
Among these attendances were 7 (18.9%) in which a Clin-AC was recorded and in one
quarter (27.0%, n=10) of all the attendances the patient was hypotensive on arrival (Table 2)
After reclassification, 9 (24.3%) of the T1DM patients were considered to have had a “true
AC”. Nearly two thirds (64.9%, n=24) had hyperglycaemia; 18.9%, (n=7) had
hypoglycaemia, both of which were significantly higher than those found in non-T1DM PAI
patients (Table 2). DKA was diagnosed in 11 (29.7%) presentations. Patients with both
T1DM and PAI had no record of IM hydrocortisone use, and only 5 (13.5%) had used oral
glucocorticoid dose escalation prior to attendance at hospital; in 1 presentation the patient had
increased their insulin and 2 had increased their glucose, with another 5 patients being given
glucose in the ambulance.
Comorbid cardiovascular disease was more prevalent in older patients (mean age (sd)
with CVD: 71.0 (10.5) years and without: 50.4 (19.2) years, p<0.0001), as was T2DM (mean
age with T2DM: 63.6 (48.9) years and without: 48.9 (21.0) years, p<.0001) and thyroid
disease (mean age with thyroid disease: 61.4 (17.5) and without: 45.3 (18.2) years,
p<0.0001). In addition, among older patients, the acute symptoms of confusion (mean age
(sd) with confusion: 72.1 (14.2) and without: 52.4 (19.3) years, p<0.0001) and reduced
consciousness (mean age (sd) with reduced consciousness: 63.9 (16.4) and without: 51.8
(19.6), p<0.0001) were more common. By comparison, patients who were hypotensive were
significantly younger than normotensive patients (47.5 (19.9) and 56.4 (18.8) years
respectively, p<0.01). Similarly, patients who had vomiting were younger than patients who
did not (46.8 (18.7) years and 59.9 (18.2) years respectively, p<0.0001), as were patients who
had abdominal pain on presentation (with pain: mean age (sd) 50.0 (19.7) years and without
55.9 (19.2) years, p<0.05). In addition, patients who had used any form of stress dosing were
younger than those who had not (41.2 (21.0) years and 56.4 (18.2) years respectively,
p<0.0001). The age distribution of patients with Clin-AC, hypotension and who had used
stress dosing is shown in Figure 1.
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Comorbid Disease

Predictors of Stress Dosing

Logistic regression modelling was used to predict which demographic or disease-related
factors were associated with the use of stress dosing in this population. Logistic models
showed that three factors were independent predictors of the use of dose escalation. These
were patient age: OR 0.96 (0.94, 0.98), for each year of increasing age; vomiting: OR=2.76
(1.28,5.98); and the number of presentations: OR=1.05 (1.01,1.09) for each extra
presentation.
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Vomiting and Diarrhoea

There were 120 (47.6%) presentations in which the patient had vomiting but in only 33
(27.5%) of these had the patient used any form of dose escalation and, in only 5 cases, was
IM hydrocortisone used. Diarrhoea was less frequently reported, affecting 53 (21.0%)
attendees. Of these, only 5 (9.4%) used any form of stress dosing - 2 used IM and 3 used oral
stress dosing. Most of the patients (90.6%, n=48) who had diarrhoea also had vomiting.
Almost all (95%, n=114) patients who had vomiting were given IV hydrocortisone, as were
all patients with diarrhoea. Of those who reported vomiting, 35.8% (n=43) were classified as
having a clin-AC and 40.8% (n=49) were hypotensive on admission.
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This comprehensive study of all presentations by patients with PAI to a referral hospital in a
large regional area demonstrated that pre-emergent domiciliary management of AI by stress
dosing was attempted by only a minority (33.9%) of patients and, that among those who used
dose escalation, the recommended strategies were used inconsistently across the illness
episodes. When all attendances at hospital by these patients were considered, oral stress
dosing was used in fewer than one in five presentations and in only 2.8% of the total
attendances did a patient use IM hydrocortisone prior to arrival. Nearly one quarter of the
presentations included a clinician diagnosis of an AC. Patient age was strongly associated
with stress dosing attempts, which were made more frequently by younger rather than older
patients. Use of dose escalation was more likely to have occurred with an increasing number
of prior presentations to hospital.
A high proportion of presentations (25.0%) were associated with a clinician-derived
AC diagnosis and, although there appeared to be some misclassification of the syndrome of
symptomatic AI as an actual AC among these, the proportion of presentations that included
symptoms indicative of acute AI/AC was considerable. Half the patients diagnosed with an
AC by their treating clinician had hypotension (sBP <100mmHg), suggesting that there may
still be confusion about the diagnostic criteria that are used to define an AC (9,15) and
highlighting the value and importance of ongoing education about AI and its management
(18). When the presenting features were reviewed and patients were reclassified based on the
presence of hypotension, there were 56 patients (18.8%) who were considered to have
experienced an actual AC. Hypotension was more common in younger patients;
hyponatraemia was diagnosed in 39.3% and hyperkalaemia in 14.7%. Both absolute (sBP
less than 100mmHg) and relative (> 20mmHG lower than usual sBP) are considered
indicative of an AC but, in this analysis, we were unable to assess relative hypotension (9).
This may have affected the estimation of hypotension in older patients especially, given the
elevation in blood pressure with increasing age.
Infection has been shown to be a major cause of AC episodes in a number of studies
and was found to be associated with 45.2% of attendances in this population (8,19). Vomiting
and diarrhoea are particularly hazardous in AI because patients may not absorb either their
usual glucocorticoid replacement or any oral stress doses and, thus, are at increased risk of an
AC. In these situations, IM or even SC use of hydrocortisone is recommended (9,13,14).
However, in this population, self-management strategies were either not executed at all or
implemented in a way that would be potentially ineffective. This is consistent with the levels
of preparedness reported in other populations (20, 21), but is in contrast to the higher use of
IM hydrocortisone by children with congenital adrenal hyperplasia attending the paediatric
hospital on the same campus for treatment of an acute illness (22). In the present study,
among patients who were vomiting, only a minority (27.5%) reported some form of stress
dosing and, among those who did, only 5 used IM hydrocortisone. Hypotension on arrival to
hospital was found in 40.8% of patients with vomiting in this study, highlighting the risks
posed by non-absorption of oral glucocorticoids and illustrating the importance of parenteral
glucocorticoid administration when there is vomiting and/or diarrhoea (9,15).
Younger patients were found to be more likely to have some of the acute symptoms of
an AC (vomiting, abdominal pain and hypotension) than older patients in this study. In
addition, they were found to be more likely to use oral stress dosing strategies than the older
patients, although these were likely to be ineffective or only partially effective because of the
higher incidence of acute gastrointestinal symptoms in the younger patients. By comparison,
older patients had a greater burden of chronic comorbid disease such as cardiovascular
disease and T2DM and were more likely to present with confusion or reduced consciousness.
While ACs were diagnosed in all age groups and stress dosing was underused, the underlying
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causes may differ between the age groups and, therefore, any interventions to reduce AC risk
may need to be tailored accordingly (9, 23). In younger people, particularly those who have
been managed in paediatric settings, factors such as missing medications and medical
appointments and poor adherence to prevention strategies may contribute, especially during
the transition from paediatric to adult care arrangements (9,24,25,26). In contrast, among
older patients, higher levels of comorbid conditions, social isolation and cognitive issues may
make preventive strategies more difficult to implement (21,23).
Those patients with PAI and comorbid T1DM had a comparable proportion of
admissions with “true AC” diagnoses (24.3%) to patients with PAI only but there were also
11 (29.7%) patients with T1DM who had a diagnosis of DKA, meaning that half of these
patients attended hospital with an acute metabolic disorder. Hypoglycaemia was also
identified in 18.9% of the T1DM patients on arrival at hospital. Patients with combined
disease have been found to be at increased risk of AC events (12) which may be due to the
complexities of managing the demands of both disorders, especially during an acute illness.
The patients in this study with combined disease were no more likely to use oral
glucocorticoid dose escalation than patients with PAI alone and none used IM
hydrocortisone. In addition, only 1 patient had increased their insulin dose and 2 had given
themselves glucose, highlighting the need for improved self-management in patients with
combined disease.
While the results from this study represent an evaluation of the illness experience of
all patients attending the regional referral hospital, they are likely to represent an
underestimate of the true range of PAI-related morbidity in this population, as some patients
may have had other episodes treated elsewhere and others may have managed their AI at
home without the need for hospitalisation. In addition, given that the patients in this study
were drawn from one large regional area, the generalisability of these results to other
populations is uncertain. ACs in this analysis were those identified and diagnosed as such by
the treating clinician and may be affected by misclassification bias. To address this, the
incidence of AC was also assessed based on the presence of hypotension without an obvious
non-AI cause. Further, although the records were assessed thoroughly, there may have been
episodes of stress dosing that were unreported or undocumented, resulting in an
underestimate of the true rate of dose escalation in this population.
The reason for the disappointing levels of stress dose utilisation in this sample of
patients could not be identified definitively in this analysis. While there were no formal
educational programs for AI patients in this area over the period of the study, each patient
had access to medical practitioners and specialist endocrinologists, although the extent to
which patients accessed routine medical care could not be determined. Treatment guidelines
for both PAI and T1DM are published, with AI recommendations including the provision of
education on oral stress dosing and IM injection of hydrocortisone by the patient and/or their
carer, and the use of medical identification jewellery and a steroid identification card.
However, it has been shown in Australia and elsewhere that these are not used by all patients
(21,25,27,28). In this study, a positive effect of cumulative previous presentations to hospital
on the use of stress dosing was identified. This phenomenon has been found previously and
indicates that there may be an experiential component to the development of stress dosing
expertise among patients with AI (22).
In conclusion, the results of this study demonstrate clear shortfalls in the patient-initiated
management of AI during acute illness in patients living in a large regional area with a
comprehensive endocrine service. Adrenal crises are considered to be a cause of anxiety for
many patients with AI, but in this population, it was found that a substantial number of
patients appeared not to use any form of dose escalation and a proportion of those who did
use oral stress dosing would have benefited from self-administered parenteral hydrocortisone.
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Increased efforts directed at understanding the barriers to the effective implementation of AC
prevention strategies by different sub-groups of patients may reduce the incidence of ACs.
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Figure 1. Adrenal Crisis, Hypotension and Stress Dose Usage among Hospital Attendees with
PAI to a Regional Hospital, NSW 2000-2017.
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Total Presentations
Sex
Female
Male
Age Group
18-29
30-39
40-49
50-59
60-69
70+
Ambulance
AC recorded
Admissions
Principal Diagnosis
Infection
Trauma
AI
Gastroenteritis
Comorbid Conditions
Asthma/COPD
Cardiovascular Disease
Thyroid
T2DM
Management
PO stress dosing
IM stress dosing
Any stress dosing
IV Hydrocortisone
Surgical intervention
DKA recorded
Mortality
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Table 1. Demographic and Disease Characteristics of Hospital Attendances for Patients with
PAI to a Regional Hospital, NSW 2000-2017.
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Table 2. Signs, Symptoms and Biochemistry of Hospital Attendances for Patients with PAI to
a Regional Hospital, NSW 2000-2017.
PAI only N (%)
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Signs and Symptoms
Hypotension
Fever
Vomiting
Diarrhoea
Abdominal pain
Reduced level of consciousness
Confusion
Lethargy
Dehydration
Biochemistry
Hypoglycaemia
Hyperglycaemia
Hyponatraemia
Hyperkalaemia
Acidosis
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